Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 140

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 140
---

and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts denominated in currencies other than
the dollar are re-measured into dollars in accordance with ASC No. 830, “Foreign Currency Matters”. All transaction gains
and losses from the re-measurement of monetary balance sheet items are reflected in the consolidated statement of comprehensive loss as
financial income or expenses, as appropriate.

| f. | Cash and cash equivalents: |

Cash equivalents
are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition.

| g. | Property and equipment, net: |

Property and
equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated
useful lives of the assets at the following rates:

|                                    |     | % |    |
| Computers and electronic equipment |     |   | 33 |

| h. | Impairment of long-lived assets: |

The Company’s
long-lived assets are reviewed for impairment in accordance with Accounting Standards Codification (“ASC”) 360, “Property,
Plant and Equipment”. Whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted
cash flows expected to be generated by the assets. If such asset is considered to be impaired, the impairment to be recognized is measured
by the amount by which the carrying amount of the asset exceeds its fair value.

<div align='center'>F-36</div>

REVIUM RX.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES (Cont.)

Assets to be
disposed of are reported at the lower of the carrying amount or fair value less costs to sell. During the years ended December 31, 2023,
and 2022, no impairment losses have been identified.

| i. | Research and development expenses: |

Research and
development expenses are charged to the statement of comprehensive loss as incurred.

In-Process
Research and Development assets, acquired in an asset acquisition (i.e., assets acquired outside a business combination transactions)
that are to be used in a research and development project which are determined not to have an alternative future use are charged to expense
at